Chinese Psoriasis Real World Evidence Research
A Real World Evidence Study in Chinese Psoriasis Patients
1 other identifier
observational
10,000
1 country
29
Brief Summary
This research is a multicenter,observational study under real world settings in patients diagnosed as psoriasis by dermatologist in the clinic. As patient's choice of medication should be fully respected, all the patients can choose the treatments they prefer, like phototherapy, traditional systemic therapy or biologics. And the study was conducted to compare the effectiveness among different choices of medication in Chinese psoriasis patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jul 2020
Longer than P75 for all trials
29 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 26, 2020
CompletedStudy Start
First participant enrolled
July 8, 2020
CompletedFirst Posted
Study publicly available on registry
July 10, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 13, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 30, 2030
January 5, 2024
January 1, 2024
10 years
June 26, 2020
January 4, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
The percentage of patients who achieved a PASI reduction of 100% (PASI 100)
Psoriasis Area and Severity Index includes scores of erythema, infiltration and desquamation, weighted by area of involvement in each regions (head and neck, upper extremities, trunk, lower extremities), with higher PASI scores indicating worse condition. The percentage of patients who achieved a PASI reduction of 100% (PASI 100) will be measured.
6 months
Secondary Outcomes (9)
The percentage of patients who achieved a PASI reduction of 100% (PASI 100)
6 months and 12 months
The percentage of patients who achieved a PASI reduction of 75% (PASI 75)
6 months and 12 months
The percentage of patients who achieved a PASI reduction of 50% (PASI 50)
6 months and 12 months
static Physician Global Assessment (sPGA) = 0
6 months and 12 months
static Investigator Global Assessment (sIGA) = 0
6 months and 12 months
- +4 more secondary outcomes
Study Arms (1)
Psoriasis
This is a non-interventional study (NIS). All the patients diagnosed as psoriasis by the dermatologists in the clinic are included in this study no matter what kind of treatment they adopt.
Interventions
Eligibility Criteria
All the patients diagnosed as psoriasis by dermatologist in clinic were under treatment or willing to be treated.
You may qualify if:
- all the patients diagnosed as psoriasis by dermatologist in clinic.
You may not qualify if:
- None
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (29)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, 310000, China
Beijing Children's Hospital Affiliated to Capital Medical University
Beijing, China
the First Affiliated Hospital of Chongqing Medical University
Chongqing, China
the First Affiliated Hospital of Fujian Medical University
Fujian, China
General Hospital of Lanzhou Military Region
Gansu, China
Sun Yat-sen Memorial Hospital
Guangdong, China
The Peoples' Hospital of Guangxi Zhuang Autonomous Region
Guangxi, China
the Affiliated Hospital of Guizhou Medical University
Guizhou, China
The Fifth People's Hospital of Hainan Province
Hainan, China
the First Hospital of Hebei Medical University
Hebei, China
the Second Affiliated Hospital of Harbin Medical Unviersity
Heilongjiang, China
Henan Provincial Peoples' Hospital
Henan, China
the Affiliated Hospital of Inner Mongolia Medical University
Hohhot, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Hubei, China
Xiangya Hospital, Central South University
Hunan, China
the Second Affiliated Hospital of Nanchang University
Jiangxi, China
Yanbian University Hospital
Jilin, China
Institute of Dermatology, Chinese Academy of Medical Sciences
Nanjing, China
Xining First Hospital
Qinghai, China
Shandong Provincial Hospital for Skin Diseases
Shandong, China
Shanghai Dermatology Hospital
Shanghai, China
Taiyuan Central Hospital
Shanxi, China
the Second Affiliated Hospital of Xi'an Jiaotong University
Shanxi, China
the First hospital of China Medical University
Shenyang, China
Sichuan Provincial People's Hospital
Sichuan, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, China
First Affiliated Hospital, School of Medicine, Shihezi University
Xinjiang, China
General Hospital of Ningxia Medical University
Yinchuan, China
the Second Affiliated Hospital of Kunming Medical University
Yunnan, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator, Head of Dermatology
Study Record Dates
First Submitted
June 26, 2020
First Posted
July 10, 2020
Study Start
July 8, 2020
Primary Completion (Estimated)
July 13, 2030
Study Completion (Estimated)
July 30, 2030
Last Updated
January 5, 2024
Record last verified: 2024-01